Novel N-chloroacetyl-2-pyrazoline analogs with 2-naphthyl and ferrocenyl groups: targeting histamine receptor H1 to overcome colorectal cancer drug resistance

Abstract

Aim: This study investigates the anticancer activity of naphthalene- and ferrocene-based 2-pyrazolines against colorectal cancer (CRC) cell lines and assesses their potential to overcome chemotherapy resistance.

Methods: Several 2-pyrazoline derivatives were synthesized and tested for anticancer activity across various cell lines, including p53 wild-type (WT) and knockout (KO) colon cancer cells and vinblastine-resistant KB-V1 cervix carcinoma cells. Compounds Clac10 (5c) and Clac12 (5e) were studied for their effects on colony and spheroid formation, cell cycle, and apoptosis. Molecular docking and cellular thermal shift assays explored their binding to histamine receptor H1 (HRH1). In vivo antitumor efficacy was tested on HCT116 xenografts in NSG mice.

Results: Compounds Clac10 and Clac12 significantly inhibited the proliferation of both p53 WT and KO colon cancer cells, as well as drug-resistant KB-V1 cells. When combined with 5-fluorouracil (5-FU), they showed synergistic antiproliferative effects in HCT and DLD1 cells. These compounds reduced colony and spheroid formation, induced cell cycle arrest, and promoted apoptosis by downregulating cyclin D1 and antiapoptotic proteins [B-cell lymphoma-extra large (Bcl-XL), B-cell lymphoma 2 (Bcl-2), myeloid cell leukemia 1 (Mcl-1)]. Molecular docking and thermal shift assays confirmed binding to HRH1, affecting histamine-induced extracellular signal-regulated kinase (ERK) and glycogen synthase kinase 3 beta (GSK3B) signaling. In vivo, Clac10 significantly reduced HCT116 xenograft growth, decreased Ki-67 and phosphorylated-glycogen synthase kinase 3 beta (p-GSK3B) levels, and increased cleaved caspase-3.

Conclusion: Naphthalene-based 2-pyrazoline compounds Clac10 and Clac12 showed a potent anticancer activity against colon cancer lines. They inhibit tumor growth by targeting HRH1 signaling, indicating potential as CRC therapies and resistance-overcoming agents. Further studies are needed to explore their clinical potential.

Keywords

2-Pyrazoline / multi-component reaction / drug resistance / apoptosis / xenograft model / colon cancer / HRH1 / histamine

References

[1] Sung H,Siegel RL.Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin2021;71:209-49

[2] Wang Q,Chen G.Drug resistance in colorectal cancer: from mechanism to clinic.Cancers2022;14:2928 PMCID:PMC9221177

[3] Therachiyil L,Sahir F.Dysregulated phosphorylation of p53, autophagy and stemness attributes the mutant p53 harboring colon cancer cells impaired sensitivity to oxaliplatin.Front Oncol2020;10:1744 PMCID:PMC7485421

[4] Grassilli E.Emerging actionable targets to treat therapy-resistant colorectal cancers.Cancer Drug Resist2022;5:36-63 PMCID:PMC8992594

[5] Rainho MA,de Amorim ÍSS,Thole AA.Mitochondria in colorectal cancer stem cells - a target in drug resistance.Cancer Drug Resist2023;6:273-83 PMCID:PMC10344721

[6] Shi Z,Engevik MA.Distinct roles of histamine H1- and H2-receptor signaling pathways in inflammation-associated colonic tumorigenesis.Am J Physiol Gastrointest Liver Physiol2019;316:G205-16 PMCID:PMC6383385

[7] Zhao J,Yin C.Upregulation of histamine receptor H1 promotes tumor progression and contributes to poor prognosis in hepatocellular carcinoma.Oncogene2020;39:1724-38 PMCID:PMC7033043

[8] Li H,Li Q.The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.Cancer Cell2022;40:36-52.e9 PMCID:PMC8779329

[9] Zhong P,Oyama K.Blockade of histamine receptor H1 augments immune checkpoint therapy by enhancing MHC-I expression in pancreatic cancer cells.J Exp Clin Cancer Res2024;43:138 PMCID:PMC11077718

[10] Borowy CS.Antihistamine toxicity. Treasure Island (FL): StatPearls Publishing; 2023.

[11] Vitaku E,Njardarson JT.Analysis of the structural diversity, substitution patterns, and frequency of nitrogen heterocycles among U.S. FDA approved pharmaceuticals.J Med Chem2014;57:10257-74

[12] Zhang Y,Zhang N,Ye Y.Recent advances in the development of pyrazole derivatives as anticancer agents.Int J Mol Sci2023;24:12724 PMCID:PMC10454718

[13] Matiadis D.Pyrazoline hybrids as promising anticancer agents: an up-to-date overview.Int J Mol Sci2020;21:5507 PMCID:PMC7432644

[14] Yusuf M.Synthetic and biological studies of pyrazolines and related heterocyclic compounds.Arab J Chem2014;7:553-96

[15] Farooq S.One-pot and two-pot synthesis of chalcone based mono and bis-pyrazolines.Tetrahedron Lett2020;61:151416

[16] Nepali K,Ojha R.Effect of ring A and ring B substitution on the cytotoxic potential of pyrazole tethered chalcones.Med Chem Res2012;21:2990-7

[17] Padhye S,Oswal N.Fluorinated 2’-hydroxychalcones as garcinol analogs with enhanced antioxidant and anticancer activities.Bioorg Med Chem Lett2010;20:5818-21

[18] Singh P,Pant GJN.Synthesis and characterization of novel 1-chloroacetyl derivatives of 2-pyrazolines.Heterocycl Commun2011;17:61-3

[19] Divekar K,Kavitha N,Devgun M.Synthesis and evaluation of some new pyrazole derivatives as antimicrobial agents.Res J Pharm Technol2010;3:1039-43

[20] Gervaz P.Therapeutic potential of the anti-angiogenesis drug TNP-470.Int J Exp Pathol1998;79:359-62 PMCID:PMC3220376

[21] Shushan A,Mishani E,Klein BY.Inhibition of leiomyoma cell proliferation in vitro by genistein and the protein tyrosine kinase inhibitor TKS050.Fertil Steril2007;87:127-35

[22] Fumarola C,Castelli R.Expanding the arsenal of FGFR inhibitors: a novel chloroacetamide derivative as a new irreversible agent with anti-proliferative activity against FGFR1-amplified lung cancer cell lines.Front Oncol2019;9:179 PMCID:PMC6443895

[23] Ramkumar K,Kyani A.Mechanistic evaluation and transcriptional signature of a glutathione S-transferase omega 1 inhibitor.Nat Commun2016;7:13084 PMCID:PMC5059489

[24] Tsuboi K,Speers AE.Potent and selective inhibitors of glutathione S-transferase omega 1 that impair cancer drug resistance.J Am Chem Soc2011;133:16605-16 PMCID:PMC3226709

[25] Randolph JT,Han F.Discovery of a potent chloroacetamide GPX4 inhibitor with bioavailability to enable target engagement in mice, a potential tool compound for inducing ferroptosis in vivo.J Med Chem2023;66:3852-65

[26] Lee HY,Horning BD,Ulanovskaya OA.Covalent inhibitors of nicotinamide N-methyltransferase (NNMT) provide evidence for target engagement challenges in situ.Bioorg Med Chem Lett2018;28:2682-7

[27] Zhang P,Yu L,Zhu C.Developing protein arginine methyltransferase 1 (PRMT1) inhibitor TC-E-5003 as an antitumor drug using INEI drug delivery systems.Drug Deliv2020;27:491-501 PMCID:PMC7170320

[28] Kim E,Park JG.Protein arginine methyltransferase 1 (PRMT1) selective inhibitor, TC-E 5003, has anti-inflammatory properties in TLR4 signaling.Int J Mol Sci2020;21:3058 PMCID:PMC7246892

[29] Anchoori RK,Tseng SH.Structure-function analyses of candidate small molecule RPN13 inhibitors with antitumor properties.PLoS One2020;15:e0227727 PMCID:PMC6961910

[30] Cogoi S,Shchekotikhin AE.Potent apoptotic response induced by chloroacetamidine anthrathiophenediones in bladder cancer cells.J Med Chem2015;58:5476-85

[31] Makar S,Singh SK.Naphthalene, a versatile platform in medicinal chemistry: sky-high perspective.Eur J Med Chem2019;161:252-76

[32] Schmitt F,Biersack B.Halogenated naphthochalcones and structurally related naphthopyrazolines with antitumor activity.Bioorg Med Chem Lett2016;26:5168-71

[33] Ethiraj KR,Krishnakumar V,Nawaz Khan F.Synthesis and cytotoxicity study of pyrazoline derivatives of methoxy substituted naphthyl chalcones.Res Chem Intermed2013;39:1833-41

[34] Sánchez Maya AB, Pérez-Melero C, Salvador N, Peláez R, Caballero E, Medarde M. New naphthylcombretastatins. Modifications on the ethylene bridge.Bioorg Med Chem2005;13:2097-107

[35] Ornelas C.Ferrocene-based drugs, delivery nanomaterials and fenton mechanism: state of the art, recent developments and prospects.Pharmaceutics2023;15:2044 PMCID:PMC10458437

[36] Li L,Sun J.The antiproliferative activity of ferrocene derivatives against drug- resistant cancer cell lines: a mini review.Curr Top Med Chem2021;21:1756-72

[37] Wu X,Kostetski I.Antiplasmodial activity of ferrocenyl chalcones: investigations into the role of ferrocene.Eur J Pharm Sci2006;27:175-87

[38] Spencer J,Wang M.Synthesis and biological evaluation of JAHAs: ferrocene-based histone deacetylase inhibitors.ACS Med Chem Lett2011;2:358-62 PMCID:PMC3093745

[39] Philipova I,Momekov G,Stavrakov G.Ferrocene modified analogues of imatinib and nilotinib as potent anti-cancer agents.RSC Med Chem2023;14:880-9 PMCID:PMC10211329

[40] Wu X,Go ML.Antimalarial activity of ferrocenyl chalcones.Bioorg Med Chem Lett2002;12:2299-302

[41] Harkov S,Atamanyuk V,Lesyk R.Synthesis and biological activity of isatines bearing thiazolidinone and pyrazoline moieties.Pharmacia2013;60:8-18Available from: https://www.researchgate.net/publication/287329904_Synthesis_and_biological_activity_of_isatines_bearing_thiazolidinone_and_pyrazoline_moieties. [Last accessed on 8 Apr 2026]

[42] Dandawate P,Khan EM,Padhye S.Synthesis, characterization and anti-tubercular activity of ferrocenyl hydrazones and their β-cyclodextrin conjugates.Carbohydr Polym2014;108:135-44

[43] Ma J,Ghosh H.Superior anticancer and antifungal activities of new sulfanyl-substituted niclosamide derivatives.Biomedicines2024;12:1621 PMCID:PMC11275179

[44] Chen X,Long D,Shen F.The Cdc2/Cdk1 inhibitor, purvalanol A, enhances the cytotoxic effects of taxol through Op18/stathmin in non-small cell lung cancer cells in vitro.Int J Mol Med2017;40:235-42

[45] Ghosh H,Schobert R,Biersack B.Fluorinated and N-acryloyl-modified 3,5-Di[(E)-benzylidene]piperidin-4-one curcuminoids for the treatment of pancreatic carcinoma.Pharmaceutics2023;15:1921 PMCID:PMC10385166

[46] Landegren U.Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens.J Immunol Methods1984;67:379-88

[47] Oberhuber N,Nitzsche B.Synthesis and anticancer evaluation of new indole-based tyrphostin derivatives and their (p-cymene)dichloridoruthenium(II) complexes.Int J Mol Sci2023;24:854 PMCID:PMC9821196

[48] Ianevski A,Aittokallio T.SynergyFinder 3.0: an interactive analysis and consensus interpretation of multi-drug synergies across multiple samples.Nucleic Acids Res2022;50:W739-43 PMCID:PMC9252834

[49] Ianevski A,Gautam P.Prediction of drug combination effects with a minimal set of experiments.Nat Mach Intell2019;1:568-77 PMCID:PMC7198051

[50] Dandawate P,Panovich P.Cucurbitacin B and I inhibits colon cancer growth by targeting the Notch signaling pathway.Sci Rep2020;10:1290 PMCID:PMC6987129

[51] Franken NA,Stap J,van Bree C.Clonogenic assay of cells in vitro.Nat Protoc2006;1:2315-9

[52] Bhattacharyya S,Covarrubias-Zambrano O.Anticancer activity of novel difluorinated curcumin analog and its inclusion complex with 2-hydroxypropyl-β-cyclodextrin against pancreatic cancer.Int J Mol Sci2023;24:6336 PMCID:PMC10093935

[53] Dandawate P,Ghosh C.Diphenylbutylpiperidine antipsychotic drugs inhibit prolactin receptor signaling to reduce growth of pancreatic ductal adenocarcinoma in mice.Gastroenterology2020;158:1433-49.e27 PMCID:PMC7103550

[54] Schleser SW,Hörner G.New 4,5-diarylimidazol-2-ylidene-iodidogold(I) complexes with high activity against esophageal adenocarcinoma cells.Int J Mol Sci2023;24:5738 PMCID:PMC10052191

[55] Shimamura T,Weyand S.Structure of the human histamine H1 receptor complex with doxepin.Nature2011;475:65-70 PMCID:PMC3131495

[56] Trott O.AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading.J Comput Chem2010;31:455-61 PMCID:PMC3041641

[57] Alexander N,Meiler J.bcl::Cluster : a method for clustering biological molecules coupled with visualization in the Pymol Molecular Graphics System.IEEE Int Conf Comput Adv Bio Med Sci2011;13-8 PMCID:PMC5091839

[58] Jafari R,Axelsson H.The cellular thermal shift assay for evaluating drug target interactions in cells.Nat Protoc2014;9:2100-22

[59] Krishnamachary B,Dandawate P.Targeting transcription factor TCF4 by γ-Mangostin, a natural xanthone.Oncotarget2019;10:5576-91 PMCID:PMC6771460

[60] Altıntop MD,Özdemir A.Design, synthesis, and evaluation of a new series of 2-pyrazolines as potential antileukemic agents.ACS Omega2023;8:42867-77 PMCID:PMC10652261

[61] Hientz K,Bhakta-Guha D.The role of p53 in cancer drug resistance and targeted chemotherapy.Oncotarget2017;8:8921-46 PMCID:PMC5352454

[62] Pardini B,Naccarati A.5-Fluorouracil-based chemotherapy for colorectal cancer and MTHFR/MTRR genotypes.Br J Clin Pharmacol2011;72:162-3 PMCID:PMC3141199

[63] Lee EF,Tran S.BCL-XL and MCL-1 are the key BCL-2 family proteins in melanoma cell survival.Cell Death Dis2019;10:342 PMCID:PMC6482196

[64] Zanoni M,Arienti C.3D tumor spheroid models for in vitro therapeutic screening: a systematic approach to enhance the biological relevance of data obtained.Sci Rep2016;6:19103 PMCID:PMC4707510

[65] Goldman MJ,Hastie M.Visualizing and interpreting cancer genomics data via the Xena platform.Nat Biotechnol2020;38:675-8 PMCID:PMC7386072

[66] Jain R,Saini DK.ERK activated by Histamine H1 receptor is anti-proliferative through spatial restriction in the cytosol.Eur J Cell Biol2016;95:623-34

[67] Diks SH,Diab RM.Activation of the canonical beta-catenin pathway by histamine.J Biol Chem2003;278:52491-6

[68] Miller I,Yang C.Ki67 is a graded rather than a binary marker of proliferation versus quiescence.Cell Rep2018;24:1105-12.e5 PMCID:PMC6108547

[69] Chu XY,Ueda K,Akiyama S.Active efflux of CPT-11 and its metabolites in human KB-derived cell lines.J Pharmacol Exp Ther1999;288:735-41

[70] Matsunaga T,Saito H.Significance of aldo-keto reductase 1C3 and ATP-binding cassette transporter B1 in gain of irinotecan resistance in colon cancer cells.Chem Biol Interact2020;332:109295

[71] Chu X,Ning J.Cancer stem cells: advances in knowledge and implications for cancer therapy.Signal Transduct Target Ther2024;9:170 PMCID:PMC11224386

[72] Zhou Y,Wang H.Cancer stem cells in progression of colorectal cancer.Oncotarget2018;9:33403-15 PMCID:PMC6161799

[73] Chai Y,Zhang S.The effective combination therapies with irinotecan for colorectal cancer.Front Pharmacol2024;15:1356708 PMCID:PMC10875015

[74] Elmore S.Apoptosis: a review of programmed cell death.Toxicol Pathol2007;35:495-516 PMCID:PMC2117903

[75] Niu Y,Lu JJ.PTEN activation by DNA damage induces protective autophagy in response to cucurbitacin B in hepatocellular carcinoma cells.Oxid Med Cell Longev2016;2016:4313204 PMCID:PMC5155108

[76] Zeng L,Pi C.Novel ferrocene derivatives induce apoptosis through mitochondria-dependent and cell cycle arrest via PI3K/Akt/mTOR signaling pathway in T cell acute lymphoblastic leukemia.Cancers2021;13:4677 PMCID:PMC8467123

[77] Choudhary GS,Mazumder S.MCL-1 and BCL-xL-dependent resistance to the BCL-2 inhibitor ABT-199 can be overcome by preventing PI3K/AKT/mTOR activation in lymphoid malignancies.Cell Death Dis2015;6:e1593 PMCID:PMC4669737

[78] Jun SY,Yoon N,Byun JH.Prognostic potential of cyclin D1 expression in colorectal cancer.J Clin Med2023;12:572 PMCID:PMC9867305

[79] Montalto FI.Cyclin D1 in cancer: a molecular connection for cell cycle control, adhesion and invasion in tumor and stroma.Cells2020;9:2648 PMCID:PMC7763888

[80] Guo J,Fu YC.Efficacy of sequential treatment of HCT116 colon cancer monolayers and xenografts with docetaxel, flavopiridol, and 5-fluorouracil.Acta Pharmacol Sin2006;27:1375-81

[81] Jung J.Human tumor xenograft models for preclinical assessment of anticancer drug development.Toxicol Res2014;30:1-5 PMCID:PMC4007037

[82] Lazebnik YA,Desnoyers S,Earnshaw WC.Cleavage of poly(ADP-ribose) polymerase by a proteinase with properties like ICE.Nature1994;371:346-7

[83] Noble P,Al-Attar A,Scholefield J.High levels of cleaved caspase-3 in colorectal tumour stroma predict good survival.Br J Cancer2013;108:2097-105 PMCID:PMC3670501